Imagine most medicines are like keys that only fit a few locks in the body. This technology creates a new set of master keys that can open the 85% of locks that were previously impossible to unlock. It allows scientists to stop harmful proteins that drive diseases like cancer and Alzheimer's, which were once considered 'undruggable'.
Pharmaceutical companies are running out of targetable proteins, as current methods only reach 15% of the human proteome. This leaves 85% of disease-driving proteins 'undruggable', limiting treatments for cancer and Alzheimer's.
A patented platform of chemical building blocks (ProMs) and a preclinically validated drug candidate for tumor progression.
If you are a drug discovery firm dealing with the fact that only 15% of disease proteins are targetable — this project developed the ProM platform that unlocks the remaining 85% of the proteome. This allows for the creation of new drug candidates for pancreatic and breast cancer.
If you are an oncology lab dealing with drug-resistance in cancer therapies — this project developed a specific inhibitor that prevents tumor progression in vivo. This provides a way to target drivers of cancer that were previously unreachable.
If you are a specialist dealing with Alzheimer's and other chronic disorders — this project developed a platform to target proteins linked to these pathologies. It enables the design of therapeutics for diseases that currently have no effective drug options.
Based on available project data, specific pricing or cost structures for the ProM platform are not disclosed.
Yes, the project successfully demonstrated the upscaled manufacturing of ProMs and optimized the synthesis process for drug leads.
The ProM technology is described as patented, though specific licensing terms are not provided in the project data.
The platform provides chemical building blocks that can be combined into small molecule drugs to target proteins in cancer, Alzheimer's, and cardiovascular diseases.
The project ran from 2022-04-01 to 2025-03-31, focusing on preclinical validation and manufacturing scale-up.
The project is led by a single German SME, PROSION GMBH, with a 100% industry ratio. This lean structure indicates a highly focused commercial drive, as the company is building its own internal pipeline rather than relying on academic partners.
Contact PROSION GMBH in Germany regarding ProM platform licensing
Contact us to find partners for ProM-based drug development
